Diagnosis & Disease Information

Annual PSA Screening Best for Reducing Prostate Cancer Deaths

Jody A. Charnow

September 14, 2018

A study of 400,887 men in an integrated health system, the first to evaluate various PSA screening intervals and age groups, concluded that yearly screening is the interval of choice.

Prostate Cancer

Apalutamide Preserves HRQoL in Nonmetastatic CRPC

Jody A. Charnow

September 13, 2018

New analysis of the SPARTAN trial shows that apalutamide maintains health-related quality of life while lowering the risk of metastasis.

ICS 2018 Coverage

Nocturia Associated With Increased Fall Risk

Jody A. Charnow

August 30, 2018

German study revealed a 13% higher risk of falls among patients with vs without nocturia.

Next post in ICS 2018 Coverage

Diagnosis & Disease Information

Annual PSA Screening Best for Reducing Prostate Cancer Deaths

Apalutamide Preserves HRQoL in Nonmetastatic CRPC

Nocturia Associated With Increased Fall Risk

Most Transient SUI After HoLEP Resolves Within 6 Weeks